Compare Dishman Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TORRENT PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA TORRENT PHARMA DISHMAN PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 25.1 58.9 42.6% View Chart
P/BV x 3.3 6.2 53.7% View Chart
Dividend Yield % 0.7 0.8 80.7%  

Financials

 DISHMAN PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TORRENT PHARMA
Mar-18
DISHMAN PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,550 24.2%   
Low Rs1291,144 11.3%   
Sales per share (Unadj.) Rs197.8354.7 55.8%  
Earnings per share (Unadj.) Rs21.240.1 52.9%  
Cash flow per share (Unadj.) Rs34.764.2 54.1%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.81.0 76.5%  
Book value per share (Unadj.) Rs179.9273.1 65.9%  
Shares outstanding (eoy) m80.69169.22 47.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.8 33.5%   
Avg P/E ratio x11.933.6 35.3%  
P/CF ratio (eoy) x7.221.0 34.6%  
Price / Book Value ratio x1.44.9 28.4%  
Dividend payout %9.434.9 27.0%   
Avg Mkt Cap Rs m20,306227,897 8.9%   
No. of employees `0000.814.7 5.6%   
Total wages/salary Rs m5,35511,353 47.2%   
Avg. sales/employee Rs Th19,252.74,083.0 471.5%   
Avg. wages/employee Rs Th6,459.5772.3 836.4%   
Avg. net profit/employee Rs Th2,064.1461.3 447.4%   
INCOME DATA
Net Sales Rs m15,96160,021 26.6%  
Other income Rs m2652,988 8.9%   
Total revenues Rs m16,22663,009 25.8%   
Gross profit Rs m4,10313,493 30.4%  
Depreciation Rs m1,0914,086 26.7%   
Interest Rs m9443,085 30.6%   
Profit before tax Rs m2,3349,310 25.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,529 24.7%   
Profit after tax Rs m1,7116,781 25.2%  
Gross profit margin %25.722.5 114.4%  
Effective tax rate %26.727.2 98.4%   
Net profit margin %10.711.3 94.9%  
BALANCE SHEET DATA
Current assets Rs m11,01852,623 20.9%   
Current liabilities Rs m9,51752,022 18.3%   
Net working cap to sales %9.41.0 938.4%  
Current ratio x1.21.0 114.4%  
Inventory Days Days110120 92.4%  
Debtors Days Days3576 45.7%  
Net fixed assets Rs m16,30485,016 19.2%   
Share capital Rs m161846 19.1%   
"Free" reserves Rs m12,90745,376 28.4%   
Net worth Rs m14,51646,222 31.4%   
Long term debt Rs m4,18941,115 10.2%   
Total assets Rs m29,805142,432 20.9%  
Interest coverage x3.54.0 86.4%   
Debt to equity ratio x0.30.9 32.4%  
Sales to assets ratio x0.50.4 127.1%   
Return on assets %8.96.9 128.6%  
Return on equity %11.814.7 80.3%  
Return on capital %17.514.2 123.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95214,580 34.0%   
Fx outflow Rs m6973,600 19.4%   
Net fx Rs m4,25510,980 38.7%   
CASH FLOW
From Operations Rs m2,7868,942 31.2%  
From Investments Rs m-1,529-47,070 3.2%  
From Financial Activity Rs m-94134,174 -2.8%  
Net Cashflow Rs m316-3,655 -8.7%  

Share Holding

Indian Promoters % 61.4 71.5 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 7.0 52.7%  
FIIs % 12.7 12.6 100.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 8.8 251.1%  
Shareholders   46,261 26,511 174.5%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS